GlassScriptPhysician profile
Ayad A Shukur
NPI 1669518320
$517.58
in general payments reported to CMS, 2019-2025
9 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.59 · 2022: $17.78 · 2023: $199 · 2024: $79.22 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $348 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $348.00 |
| Education | $133.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $202.78 | 2025 | |
| Mallinckrodt Hospital Products INC. | $145.49 | 2023-2024 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $36.81 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $36.05 | 2024 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $34.68 | 2022-2023 | Velphoro |
| Horizon Therapeutics Plc | $18.59 | 2019 | |
| Ardelyx, INC. | $15.21 | 2024 | Ibsrela |
| Aurinia Pharma U.S., INC. | $14.37 | 2024 | Lupkynis |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayad Shukur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.